Iovance Biotherapeutics, Inc. Stock News

Iovance Biotherapetics recently obtained its first approval from the Food and Drug Administration. The company now has a potential blockbuster on its hands.

Iovance Biotherapetics recently obtained its first approval from the Food and Drug Administration. The company now has a potential blockbuster on its hands.

SAN CARLOS, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor in

The biotech published its first set of quarterly results after winning an important regulatory nod. Its revenue for the period fell notably short of pundit expectations, however.

Iovance (IOVA) reports dismal earnings in the fourth quarter. Management is in the process of commercially launching the recently approved melanoma drug Amtagvi in the United States.

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.64 per share a year ago.

Iovance (IOVA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Iovance Biotherapeutics earned approval for its first new drug, Amtagvi, on Feb. 16. Amtagvi is a first-in-class treatment that uses a patient's own immune cells to attack solid tumors.

Iovance shares have surged more than 70% in just a few days. The gains came after the biotech won approval for its very first product, one that relies on the body's own cells.

Iovance Biotherapeutics is now launching its first cell therapy drug. That's prompting financial analysts to adjust their price targets.

Analysts are bullish, on average, regarding both Ginkgo Bioworks and Iovance Biotherapeutics. Ginkgo Bioworks' cost-cutting and manufacturing scaling capabilities are being put to the test.

SAN CARLOS, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf

Shares of the biotechnology company are on pace for their best day since June 2016.

Iovance Biotherapeutics Inc (NASDAQ:IOVA) stock is up 39.5% at $12.76 at last check, after the company received  accelerated approval  from the Food and Drug Administration (FDA) for its cell ther

Iovance Biotherapeutics' stock has increased over 50% since September, following positive news about its TIL therapy for advanced melanoma. The FDA has granted approval for Iovance's TIL therapy, name